Karyopharm expands equity plans, adds PSU retention awards
Karyopharm Therapeutics Inc. reported that stockholders approved an amendment to its 2022 Equity Incentive Plan, adding 3,000,000 shares of common stock for equity awards.
Rhea-AI Filing Summary
Karyopharm Therapeutics Inc. reported that stockholders approved an amendment to its 2022 Equity Incentive Plan, adding 3,000,000 shares of common stock for equity awards. Stockholders also increased shares available under the Amended & Restated 2013 Employee Stock Purchase Plan by 1,400,000 shares.
The Board’s Compensation Committee adopted a broad-based retention program using performance-based restricted stock units, covering an aggregate of 3,838,380 PSUs for eligible employees. Awards include 343,000 PSUs for each of two tranches to President and CEO Richard Paulson, with vesting tied to specified clinical and other milestones and continued service.
Stockholders elected two Class I directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Equity plan increase: 3,000,000 shares
ESPP share increase: 1,400,000 shares
Retention PSUs total: 3,838,380 PSUs
+5 more
8 metrics
Equity plan increase
3,000,000 shares
Additional shares for 2022 Equity Incentive Plan
ESPP share increase
1,400,000 shares
Added to Amended & Restated 2013 Employee Stock Purchase Plan
Retention PSUs total
3,838,380 PSUs
Aggregate PSUs under broad-based retention program
CEO PSU awards
343,000 + 343,000 PSUs
Two performance-based awards to President and CEO
CMO PSU awards
150,000 + 150,000 PSUs
Two PSU tranches to EVP, Chief Medical Officer
CFO PSU awards
130,000 + 130,000 PSUs
Two PSU tranches to EVP, CFO and Treasurer
Equity plan vote for
10,474,681 votes
Votes for 2022 Equity Incentive Plan amendment
Auditor ratification votes for
16,695,588 votes
Votes for ratifying Ernst & Young LLP for 2026
Key Terms
performance-based restricted stock units, Equity Incentive Plan, Employee Stock Purchase Plan, broker non-votes, +2 more
6 terms
performance-based restricted stock units financial
"eligible employees will receive two retention equity awards in the form of performance-based restricted stock units"
Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.
Equity Incentive Plan financial
"amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Employee Stock Purchase Plan financial
"Amended & Restated 2013 Employee Stock Purchase Plan, as amended, to increase the number of shares"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
broker non-votes financial
"The results of the stockholders’ vote with respect to such approval were as follows ... Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
retention program financial
"approved a broad-based retention program designed to support the continued motivation, retention and incentivization"
say-on-pay financial
"stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers"
A say-on-pay is a shareholder vote that gives investors a chance to approve or disapprove a company’s executive compensation packages, typically held at annual meetings. It matters because the vote signals investor satisfaction with how leaders are paid—like customers rating how well managers are rewarded—and can push boards to change pay plans, reducing governance risk and affecting investor confidence and stock value even though the vote is usually advisory rather than legally binding.
FAQ
What equity plan changes did Karyopharm Therapeutics (KPTI) stockholders approve?
Stockholders approved an amendment to Karyopharm’s 2022 Equity Incentive Plan adding 3,000,000 additional common shares for awards. They also backed an amendment to the 2013 Employee Stock Purchase Plan, increasing its share pool by 1,400,000 shares for employee purchases.
What is Karyopharm Therapeutics (KPTI) new performance-based retention program?
Karyopharm adopted a broad-based retention program granting performance-based restricted stock units under the Amended 2022 Plan. The program covers an aggregate of 3,838,380 PSUs for eligible employees, with vesting tied to specified clinical and other milestones and each participant’s continued service with the company.
How many PSUs did Karyopharm (KPTI) grant to its CEO under the new program?
President and CEO Richard Paulson received two performance-based awards effective May 31, 2026, each covering 343,000 PSUs. One award vests upon a specified clinical milestone, while the second vests in two 50% tranches upon achieving separate milestones and satisfying continued service requirements.
Which Karyopharm (KPTI) executive officers received PSUs and in what amounts?
Executive Vice President and Chief Medical Officer Dr. Reshma Rangwala received 150,000 PSUs in each of two awards. EVP and CFO Lori Macomber and EVP, Chief Development Officer Stuart Poulton each received 130,000 PSUs for the first award and 130,000 for the second award.
What were the voting results on Karyopharm (KPTI) equity plan amendment?
The amendment to increase shares under the 2022 Equity Incentive Plan received 10,474,681 votes for, 953,411 against, and 2,593 abstentions, with 5,410,881 broker non-votes. This approval expanded the share pool available for future equity incentive awards.
Did Karyopharm Therapeutics (KPTI) stockholders approve executive compensation?
Yes, stockholders approved named executive officer compensation on an advisory basis, with 10,025,198 votes for, 1,388,274 against, and 17,213 abstentions, plus 5,410,881 broker non-votes. This advisory vote supports the company’s disclosed pay practices.
Who was elected to Karyopharm (KPTI) board and who is the auditor for 2026?
Stockholders elected Barry E. Greene and Christy J. Oliger as Class I directors for terms ending at the 2029 annual meeting. They also ratified Ernst & Young LLP as Karyopharm’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
